Poly(ADP-ribose) polymerase inhibition: A new direction for BRCA and triple-negative breast cancer?

Breast Cancer Research

Volumn 13, Issue 4, 2011, Pages

  Plummer, Ruth ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CEP 9722; E 7016; GEMCITABINE; GPI 21016; INIPARIB; INO 1001; LT 673; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PF 0367338; RUCAPARIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIPARIB; 4-IODO-3-NITROBENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; ENZYME INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

DNA REPAIR; DRUG INDICATION; DRUG MECHANISM; FATIGUE; GLIOBLASTOMA; GLIOMA; HUMAN; LUNG CANCER; MELANOMA; NAUSEA; ONCOGENE; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER; VOMITING; BREAST TUMOR; DRUG ANTAGONISM; FEMALE; GENETICS; METABOLISM; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84858783762     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2877     Document Type: Review

References (43)

1. Breast cancer - UK incidence statistics. , http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/
2. Hery C, Ferlay J, Boniol M, Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 2008, 19:1009-1018. 10.1093/annonc/mdm593, 18296422.
3. Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J, Friedlander M, Carmichael J. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009, 27(18s):CRA501.
4. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244. 10.1016/S0140-6736(10)60892-6, 20609467.
5. Audeh M, Penson R, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel J, Carmichael J, Tutt A. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009, 27(15s):5500.
6. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251. 10.1016/S0140-6736(10)60893-8, 20609468.
7. Isakoff SJ, Overmoyer B, Tung NM, Gelman RS, Giranda VL, Bernhard KM, Habin KR, Ellisen LW, Winer EP, Goss PE. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer [abstract]. J Clin Oncol 2010, 28(Suppl):1019.
8. Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Kemsley K, Carmichael J. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first-or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial [abstract]. J Clin Oncol 2010, 28(Suppl):1018.
9. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovskaya V, Sherman B, Sammons B. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009, 27(18s):3.
10. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley CR. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011, 364:205-214. 10.1056/NEJMoa1011418, 21208101.
11. Gelmon KA, Hirte HW, Robidoux A, Tonkin KS, Tischkowitz M, Swenerton K, Huntsman D, Carmichael J, MacPherson E, Oza AM. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer [abstract]. J Clin Oncol 2010, 28(Suppl):3002. 2903334, 20479400.
12. Chambon P, Weil JD, Mandel P. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid sythesizing nuclear enzyme. Biochem Biophys Res Commun 1963, 11:39-43. 10.1016/0006-291X(63)90024-X, 14019961.
13. Ame J, Rolli V, Schreiber V, Niedergang C, Apiou F, Decker P, Muller S, Hoger T, Murcia J, de Murcia G. PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 1999, 274:17860-17868. 10.1074/jbc.274.25.17860, 10364231.
14. Sodhi RK, Singh N, Jaggi AS. Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications. Vascul Pharmacol 2010, 53:77-87. 10.1016/j.vph.2010.06.003, 20633699.
15. Heale JT, Ball AR, Schmiesing JA, Kim J, Kong X, Zhou S, Hudson DF, Earnshaw WC, Yokomori K. Condensin I interacts with the PARP-1-XRCC1 complex and functions in DNA single-strand break repair. Mol Cell 2006, 21:837-848. 10.1016/j.molcel.2006.01.036, 16543152.
16. Fortini P, Pascucci B, Parlatini E, Errico MD, Dogliotti E. The base excision repair: mechanisms and its relevance for cancer susceptibility. Biochimie 2003, 85:1053-1071. 10.1016/j.biochi.2003.11.003, 14726013.
17. Dantzer F, Schreiber V, Niedergang C, Trucco C, Flatter E, De La Rubia G, Oliver J, Rolli V, Menissier-de Murcia J, de Murcia G. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 1999, 81:69-75. 10.1016/S0300-9084(99)80040-6, 10214912.
18. Rouleau M, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010, 10:293-301. 10.1038/nrc2812, 2910902, 20200537.
19. Bowman KJ, Newell DR, Calvert AH, Curtin NJ. Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 2001, 84:106-112. 10.1054/bjoc.2000.1555, 2363607, 11139322.
20. Canan Koch SS, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li J, Yu XH, Zook SE, Kumpf RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky Z. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J Med Chem 2002, 45:4961-4974. 10.1021/jm020259n, 12408707.
21. Jones C, Plummer ER. PARP inhibitors and cancer therapy - early results and potential applications. Br J Radiol 2008, 81:S2-S5. 10.1259/bjr/30872348, 18819994.
22. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008, 14:7917-7923. 10.1158/1078-0432.CCR-08-1223, 2652879, 19047122.
23. Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 2002, 45:73-85. 10.1006/phrs.2001.0935, 11846617.
24. Graziani G, Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005, 52:109-118. 10.1016/j.phrs.2005.02.013, 15911339.
25. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917. 10.1038/nature03443, 15829966.
26. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921. 10.1038/nature03445, 15829967.
27. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002, 8:571-576. 10.1016/S1471-4914(02)02434-6, 12470990.
28. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of Poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.
29. Edwards S, Brough R, Lord C, Natrajan R, Vatcheva R, Levine D, Boyd J, Reis-Filho J, Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1115. 10.1038/nature06548, 18264088.
30. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120. 10.1038/nature06633, 2577037, 18264087.
31. Sandhu SK, Wenham RM, Wilding G, McFadden M, Sun L, Toniatti C, Stroh M, Carpenter CL, de Bono JS, Schelman WR. First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers [abstract]. J Clin Oncol 2010, 28(Suppl):3001.
32. Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon JE, Bigner DD, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005, 23:7178-7187. 10.1200/JCO.2005.06.502, 16192602.
33. Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, Halbert G, Waller S, McGrath H, Gumbrell L, McElhinney RS, Donnelly D, McMurry TB, Margison GP. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2006, 12:1577-1584. 10.1158/1078-0432.CCR-05-2198, 16533784.
34. Schilsky RL, Dolan ME, Bertucci D, Ewesuedo RB, Vogelzang NJ, Mani S, Wilson LR, Ratain MJ. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 2000, 6:3025-3031.
35. Kummar S, Chen AP, Ji JJ, Allen D, Egorin MJ, Gandara DR, Lenz H, Morgan R, Newman EM, Doroshow JH. A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas [abstract]. J Clin Oncol 2010, 28(Suppl):2605.
36. Plummer R, Lorigan P, Evans J, Steven N, Middleton M, Wilson R, Snow K, Dewji R, Calvert H. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol 2006, 24:456S-456S.
37. Kummar S, Ji J, Zhang Y, Simmons D, Kinders R, Gutierrez ME, Allen D, Homeffer Y, Juwara L, Rubinstein L, Parchment RE, Murgo AJ, Chen A, Tomaszewski JE, Doroshow JH. A phase I combination study of ABT-888 and topotecan hydrochloride in adults with refractory solid tumors and lymphomas. Ann Oncol 2009, 20:42-44.
38. Giaccone G, Rajan A, Kelly RJ, Gutierrez M, Kummar S, Yancey M, Ji JJ, Zhang L, Parchment RE, Doroshow JH. A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors [abstract]. J Clin Oncol 2010, 28(Suppl):3027.
39. Mahany J, Lewis N, Heath E, LoRusso P, Mita M, Rodon J, Tolcher A, Sherman B, Bradley C, Papadopoulos K. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J Clin Oncol 2008, 26(Suppl):3579.
40. Bartsch R, Ziebermayr R, Zielinski CC, Steger GG. Triple-negative breast cancer. Wien Med Wochenschr 2010, 160:174-181. 10.1007/s10354-010-0773-6, 20473728.
41. Kopetz S, Mita M, Mok I, Sankhala K, Moseley J, Sherman B, Bradley C, Tolcher A. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J Clin Oncol 2008, 26(Suppl):3577.
42. Blakeley JO, Ye X, Grossman SA, Mikkelsen T, Rosenfeld MR, Bradley CR, Eichler AF, Nabors LB, Desideri S, Supko JG. Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma [abstract]. J Clin Oncol 2010, 28(Suppl):2012.
43. Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer. , http://sanofi-aventis.mediaroom.com/index.php?s=43&item=310